The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review.

ABSTRACT: Claudin 18 isoform 2 (CLDN18.2) is a tight junction protein expressed in normal gastric tissue and retained in gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The phase III trials SPOTLIGHT and GLOW demonstrated improved survival following the addition of the CLDN18.2-targeted antibody zolbetuximab to chemotherapy. In this systematic literature review, we summarize existing evidence for the prognostic role of CLDN18.2 and association of CLDN18.2 with patient demographic and clinicopathological characteristics in patients with advanced G/GEJ adenocarcinoma. MEDLINE, Embase, clinical trials databases, and congress abstracts were searched for interventional and noninterventional studies that evaluated CLDN18.2 for patient/disease characteristics, survival, or expression of progra

SUBMITTER: Fassan M 

PROVIDER: S-EPMC12836552 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature